Wegovy (semaglutide injection): Another weekly option, Wegovy is designed for individuals dealing with obesity or overweight conditions with associated health concerns
The syringe barrel should also have "U-100" printed on it for easy verification
The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), a phase 3 study involving 17,604 adults with overweight or obesity and pre-existing CVD but no diabetes, revealed that once-weekly subcutaneous semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared with placebo over a mean follow-up of 39.8 months, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [48]
Efficacy Zepbound is effective for managing chronic weight, obesity, and obstructive sleep apnea
Son ejemplos de casos con el mismo principio activo, pero usos distintos